Literature DB >> 10897328

Monoclonal antibodies.

P N Nelson1, G M Reynolds, E E Waldron, E Ward, K Giannopoulos, P G Murray.   

Abstract

Monoclonal antibodies are essential tools for many molecular immunology investigations. In particular, when used in combination with techniques such as epitope mapping and molecular modelling, monoclonal antibodies enable the antigenic profiling and visualisation of macromolecular surfaces. In addition, monoclonal antibodies have become key components in a vast array of clinical laboratory diagnostic tests. Their wide application in detecting and identifying serum analytes, cell markers, and pathogenic agents has largely arisen through the exquisite specificity of these unique reagents. Furthermore, the continuous culture of hybridoma cells that produce these antibodies offers the potential of an unlimited supply of reagent. In essence, when compared with the rather limited supply of polyclonal antibody reagents, the feature of a continuous supply enables the standardisation of both the reagent and the assay technique. Clearly, polyclonal and monoclonal antibodies have their advantages and disadvantages in terms of generation, cost, and overall applications. Ultimately, monoclonal antibodies are only produced when necessary because their production is time consuming and frustrating, although greatly rewarding (at least most of the time!). This is especially apparent when a monoclonal antibody can be applied successfully in a routine pathology laboratory or can aid in the clinical diagnosis and treatment of patients. In this article, the generation and application of monoclonal antibodies are demystified to enable greater understanding and hopefully formulate novel ideas for clinicians and scientists alike.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10897328      PMCID: PMC1186915          DOI: 10.1136/mp.53.3.111

Source DB:  PubMed          Journal:  Mol Pathol        ISSN: 1366-8714


  46 in total

1.  Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells.

Authors:  M S Cole; C Anasetti; J Y Tso
Journal:  J Immunol       Date:  1997-10-01       Impact factor: 5.422

2.  IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.

Authors:  D G Maloney; A J Grillo-López; C A White; D Bodkin; R J Schilder; J A Neidhart; N Janakiraman; K A Foon; T M Liles; B K Dallaire; K Wey; I Royston; T Davis; R Levy
Journal:  Blood       Date:  1997-09-15       Impact factor: 22.113

3.  Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma.

Authors:  R D Gascoyne; S A Adomat; S Krajewski; M Krajewska; D E Horsman; A W Tolcher; S E O'Reilly; P Hoskins; A J Coldman; J C Reed; J M Connors
Journal:  Blood       Date:  1997-07-01       Impact factor: 22.113

4.  Characterisation of anti-IgG monoclonal antibody A57H by epitope mapping.

Authors:  P N Nelson; O M Westwood; R Jefferis; M Goodall; F C Hay
Journal:  Biochem Soc Trans       Date:  1997-05       Impact factor: 5.407

5.  The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas.

Authors:  P Tan; B Cady; M Wanner; P Worland; B Cukor; C Magi-Galluzzi; P Lavin; G Draetta; M Pagano; M Loda
Journal:  Cancer Res       Date:  1997-04-01       Impact factor: 12.701

6.  High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers.

Authors:  S Fredersdorf; J Burns; A M Milne; G Packham; L Fallis; C E Gillett; J A Royds; D Peston; P A Hall; A M Hanby; D M Barnes; S Shousha; M J O'Hare; X Lu
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

7.  c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.

Authors:  C Carlomagno; F Perrone; C Gallo; M De Laurentiis; R Lauria; A Morabito; G Pettinato; L Panico; A D'Antonio; A R Bianco; S De Placido
Journal:  J Clin Oncol       Date:  1996-10       Impact factor: 44.544

Review 8.  The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy.

Authors:  J S Ross; J A Fletcher
Journal:  Semin Cancer Biol       Date:  1999-04       Impact factor: 15.707

9.  Fine specificity of autoantibodies to La/SSB: epitope mapping, and characterization.

Authors:  A G Tzioufas; E Yiannaki; M Sakarellos-Daitsiotis; J G Routsias; C Sakarellos; H M Moutsopoulos
Journal:  Clin Exp Immunol       Date:  1997-05       Impact factor: 4.330

10.  Combined analysis with Bcl-2 and P53 immunostaining predicts poorer prognosis in prostatic carcinoma.

Authors:  H Matsushima; T Kitamura; T Goto; Y Hosaka; Y Homma; K Kawabe
Journal:  J Urol       Date:  1997-12       Impact factor: 7.450

View more
  31 in total

1.  Epitope mapping of a monoclonal antibody against human thrombin by H/D-exchange mass spectrometry reveals selection of a diverse sequence in a highly conserved protein.

Authors:  Abel Baerga-Ortiz; Carrie A Hughes; Jeffrey G Mandell; Elizabeth A Komives
Journal:  Protein Sci       Date:  2002-06       Impact factor: 6.725

Review 2.  Demystified...recombinant antibodies.

Authors:  K A Smith; P N Nelson; P Warren; S J Astley; P G Murray; J Greenman
Journal:  J Clin Pathol       Date:  2004-09       Impact factor: 3.411

3.  Efficient generation of useful monoclonal antibodies reactive with globotriaosylceramide using knockout mice lacking Gb3/CD77 synthase.

Authors:  Yuji Kondo; Noriyo Tokuda; Keiko Furukawa; Reiko Ando; Makoto Uchikawa; Qing Zhang; Fan Xiaoyan; Koichi Furukawa
Journal:  Glycoconj J       Date:  2011-06-10       Impact factor: 2.916

Review 4.  Toll-like receptors as therapeutic targets for autoimmune connective tissue diseases.

Authors:  Jing Li; Xiaohui Wang; Fengchun Zhang; Hang Yin
Journal:  Pharmacol Ther       Date:  2013-03-24       Impact factor: 12.310

5.  Generation of polyclonal antibodies against recombinant human glucocerebrosidase produced in Escherichia coli.

Authors:  Juliana Branco Novo; Maria Leonor Sarno Oliveira; Geraldo Santana Magalhães; Ligia Morganti; Isaías Raw; Paulo Lee Ho
Journal:  Mol Biotechnol       Date:  2010-11       Impact factor: 2.695

6.  Epitope mapping of human VWF A3 recognized by monoclonal antibody SZ-123 and SZ-125 using MALDI mass spectrometry.

Authors:  Miao Jiang; Yiming Zhao; Fei Shen; Fuqiang Wang; Yang He; Changgeng Ruan
Journal:  Int J Hematol       Date:  2011-08-06       Impact factor: 2.490

7.  B7-H4 expression in various tumors determined using a novel developed monoclonal antibody.

Authors:  Yun Qian; Ling Shen; Linfang Cheng; Zhigang Wu; Hangping Yao
Journal:  Clin Exp Med       Date:  2010-12-29       Impact factor: 3.984

8.  Immunohistochemical Analysis in the Rat Central Nervous System and Peripheral Lymph Node Tissue Sections.

Authors:  Milena Z Adzemovic; Manuel Zeitelhofer; Marianne Leisser; Ulricke Köck; Angela Kury; Tomas Olsson
Journal:  J Vis Exp       Date:  2016-11-14       Impact factor: 1.355

9.  Immunization of A4galt-deficient mice with glycosphingolipids from renal cell cancers resulted in the generation of anti-sulfoglycolipid monoclonal antibodies.

Authors:  Reiko Ando; Noriyo Tokuda; Tokunori Yamamoto; Kazutaka Ikeda; Noboru Hashimoto; Ryo Taguchi; Xiaoen Fan; Keiko Furukawa; Yukio Niimura; Akemi Suzuki; Momokazu Goto; Koichi Furukawa
Journal:  Glycoconj J       Date:  2016-02-16       Impact factor: 2.916

10.  Generation and characterization of novel human IRAS monoclonal antibodies.

Authors:  Bo Wang; Ying Liu; Yajun Shan; Zhenyu Yao; Xiaolan Liu; Ruibin Su; Qihong Sun; Yuwen Cong; Jin Li
Journal:  J Biomed Biotechnol       Date:  2009-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.